Abstracts tagged "ANCA and genetics"

Abstract Number: 1942 • 2019 ACR/ARP Annual Meeting
Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Masayoshi Harigai¹, Aya Kawasaki ², Naoyuki Tsuchiya ², Ken-Ei Sada ³, Fumio Hirano ⁴, Takahiko Sugihara ⁵, Koichi Amano ⁶, Kunihiro Yamagata ⁷, Hiroaki Dobashi ⁸, Kenji Nagasaka ⁹, Tatsuya Atsumi ¹⁰, Seik-Soon Khor ¹¹, Katsushi Tokunaga ¹², Shoichi Ozaki ¹³, Seiichi Matsuo ¹⁴, Yoshihiro Arimura ¹⁵ and Hirofumi Makino ¹⁶, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁶Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Kawagoe, Japan, ⁷Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁸Kagawa University, Kagawa, Japan, ⁹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹Genome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan, ¹²National Center for Global Health and Medicine, Tokyo, Japan, ¹³St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴13. Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁵Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶Okayama University, Okayama, Japan
Background/Purpose: Clinical and serological features of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are different across geographical regions and ethnicities, which strongly indicates significant roles of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].